OPTN News and Press, OptiNose Inc. From 05/06/24

2024-05-06 08:39:30 ET More on premarket gainers & stock CytomX: CX-904 Tumor Treatment Data Might Get Ball Rolling CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town NRX Pharmaceuticals, Inc. (NRXP) Q4 2023 Earnings Call...

2024-04-25 11:50:29 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Bristol-Myers Squibb (NYSE: BMY ) layoffs are a hot topic on Thursday after the biopharmaceutical company announced major cuts coming to its workforce . Bristol-Myers S...

2024-04-25 11:07:07 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Stocks are down today and investors wondering why have come to the right place as we have all the details behind the market slump on Thursday! The first bit of news that is pulling stocks d...

2024-04-25 10:51:01 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips OptiNose (NASDAQ: OPTN ) stock is taking off on Thursday after the company provided investors with an update on XHANCE following an expansion of its use by the U.S. Food and Dru...

A look at the top 10 most actives in the United States Safe & Green Holdings Corp. (SGBX) rose 52.1% to $0.2192 on volume of 34,842,044 shares Processa Pharmaceuticals Inc. (PCSA) rose 46.9% to $2.38 on volume of 31,858,013 shares PROSHARES TRUST (SQQQ) rose 5.0% to $12.4002 on volume...

YARDLEY, Pa., April 25, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced corporate updates detailing its commercial plans and expectations for XHANCE ® (flutica...

2024-03-16 08:37:06 ET More on OptiNose OptiNose, Inc. 2023 Q4 - Results - Earnings Call Presentation OptiNose, Inc. (OPTN) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on OptiNose Historical earnings data for OptiNose Financia...

ReOpen was th e first ever large placebo-controlled clinical trial program to demonstrate statistically significant reduction of symptoms in chronic sinusitis patients without nasal polyps Clinical trial program also showed reduction in sinus inflammation and in acute exacerbati...

2024-03-08 15:00:00 ET More on the markets S&P 500: Time To Hedge, Here's How How The S&P 500 Could Actually Be Closer To 4,200 Than 5,000 SPDR S&P 500 ETF And Invesco QQQ Trust: Almost All Investors Are Crowded Into The Same Side Of The Boat ETFs...

2024-03-07 09:14:06 ET OptiNose, Inc. (OPTN) Q4 2023 Earnings Conference Call March 07, 2024 08:00 AM ET Company Participants Jonathan Neely - VP, IR & Business Development Ramy Mahmoud - CEO Conference Call Participants Thomas Flaten - Lake Street ...